⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
QURE — uniQure N.V.
Last scan (Sept. 30, 2026): price $24.51, RSI 17.54, relative volume 20.71x, MACD ⚪ No, score 50.00.
It's trading below its 200-day average, with an RSI of 17.54 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Today's volume is 20.71x average — well above normal activity, a sign of real interest. The analysts' average target price implies +178.0% upside — one of the score's strongest signals. Today it holds rank #3 in the Medium group on Smart Scanner's upside + relative volume ranking.
Price chart
QURE
Price: $24.45 · RSI (14): 22.29 · Rel. volume: 1.68x · Breakout: No
- Current price: ($24.45) — solid white line — the latest available closing price.
- Target price: ($68.16) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($22.48) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
QURE
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate,…
- Buy 11
- Hold 1
- Sell 0
Average target price: $68.16 (+178.1% vs. current price) · range $45.91 – $92.77
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
?
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Not enough data to calculate it (no recent earnings or data unavailable).
?
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
?
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
?
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
High leverage: more risk if the cost of debt rises or cash flow drops.
?
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
?
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
?
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Moves similarly to the overall market.
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.